Anticonvulsants in the treatment of anxiety - An alternative treatment option?;Antiepileptika in der therapie von angsterkrankungen - Eine mögliche therapeutische alternative?

Nervenarzt

Volumn 78, Issue 11, 2007, Pages 1274-1282

  Zwanzger, P ^a   Eser, D ^b   Rupprecht, R ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anticonvulsants; Generalized anxiety disorder; Panic disorder; Pharmacotherapy; Social phobia

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANXIETY DISORDER; DRUG EFFECT; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HUMAN; PARESTHESIA; REVIEW; SOCIAL PHOBIA; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; ANXIETY DISORDERS; BIOMEDICAL RESEARCH; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; TREATMENT OUTCOME;

EID: 36048965874     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2361-6     Document Type: Review

References (42)

1. Ballenger JC (1998) Panic disorder in primary care and general medicine. In: Rosenbaum JF, Pollack MH (eds) Panic disorder and its treatment. Dekker Inc., New York Basel Hongkong, pp 1-36
2. Ballenger JC, Burrows GD, DuPont RL Jr et al. (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 45: 413-422
3. Bandelow B (2006) Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr 11: 21-28
4. Barlow DH (2002) Anxiety and its disorders: the nature and treatment of anxiety and panic. The Guilford Press, New York London
5. Comaish IF, Gorman C, Brimlow GM et al. (2002) The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104: 195-212
6. Crane D (2003) Tiagabine for the treatment of anxiety. Depress Anxiety 18: 51-52
7. Feltner DE, Crockatt JG, Dubovsky SJ et al. (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23: 240-249
8. Gallinat J, Hegerl U (1999) [Limbic ictus as a condition for anxiety attacks]. Nervenarzt 70: 206-215
9. Goddard AW, Mason GF, Almai A et al. (2001) Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58: 556-561
10. Keck PE Jr, Taylor VE, Tugrul KC et al. (1993) Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 33: 542-546
11. Kessler RC, Chiu WT, Demler O et al. (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627
12. Lum M, Fontaine R, Elie R, Ontiveros A (1990) Divalproex sodium's antipanic effects in panic disorder. Biol Psychiatry 27: 164A
13. Malizia AL, Cunningham VJ, Bell CJ et al. (1998) Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 55: 715-720
14. Montgomery SA, Tobias K, Zornberg GL et al. (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67: 771-782
15. Pande AC, Crockatt JG, Feltner DE et al. (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160: 533-540
16. Pande AC, Davidson JR, Jefferson JW et al. (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19: 341-348
17. Pande AC, Feltner DE, Jefferson JW et al. (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24: 141-149
18. Pande AC, Pollack MH, Crockatt J et al. (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20: 467-471
19. Perucca E (2005) An introduction to antiepileptic drugs. Epilepsia (Suppl 4) 46: 31-37
20. Pohl R, Yeragani VK, Balon R, Lycaki H (1988) The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 49: 100-104
21. Pohl RB, Feltner DE, Fieve RR, Pande AC (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25: 151-158
22. Pollack MH (2004) Unmet needs in the treatment of anxiety disorders. Psychopharmacol Bull 38: 31-37
23. Pollack MH, Matthews J, Scott EL (1998) Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155: 992-993
24. Pollack MH, Roy-Byrne PP, Van Ameringen M et al. (2005) The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 66: 1401-1408
25. Primeau F, Fontaine R, Beauclair L (1990) Valproic acid and panic disorder. Can J Psychiatry 35: 248-250
26. Rickels K, Pollack MH, Feltner DE et al. (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62: 1022-1030
27. Rosenthal M (2003) Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64: 1245-1249
28. Rupprecht R, Di Michele F, Hermann B et al. (2001) Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res Brain Res Rev 37: 59-67
29. Rupprecht R, Zwanzger P (2003) [Significance of GABAA receptors for the pathophysiology and therapy of panic disorders]. Nervenarzt 74: 543-551
30. Simon NM, Worthington JJ, Doyle AC et al. (2004) An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 65: 1219-1222
31. Stoppel C, Albrecht A, Pape HC, Stork O (2006) Genes and neurons: molecular insights to fear and anxiety. Genes Brain Behav (Suppl 2) 5: 34-47
32. Tondo L, Burrai C, Scamonatti L et al. (1989) Carbamazepine in panic disorder. Am J Psychiatry 146: 558-559
33. Uhde TW, Stein MB, Post RM (1988) Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 145: 1104-1109
34. Van Ameringen M, Mancini C, Pipe B, Bennett M (2004) Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 64: 2199-2220
35. Van Ameringen M, Mancini C, Pipe B et al. (2004) An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 65: 1674-1678
36. Woodman CL, Noyes R Jr (1994) Panic disorder: treatment with valproate. J Clin Psychiatry 55: 134-136
37. Zhang W, Connor KM, Davidson JR (2005) Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 19: 551-553
38. Zwanzger P, Baghai T, Boerner RJ et al. (2001) Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 21: 539-540
39. Zwanzger P, Baghai TC, Schule C et al. (2001) Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 62: 656-657
40. Zwanzger P, Deckert J (2007) Angsterkrankungen: Ursachen, Klinik, Therapie. Nervenarzt 78: 349-360
41. Zwanzger P, Rupprecht R (2004) Vigabatrin and tiagabine might have antipanic properties. J Psychopharmacol 18: 440
42. Zwanzger P, Rupprecht R (2005) Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30: 167-175